School of Biological and Environmental Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India.
Department of Biosciences and technology (MMEC), Maharishi Markandeshwar University, Mullana (Ambala), Haryana 133203, India.
Biofabrication. 2024 Aug 29;16(4). doi: 10.1088/1758-5090/ad6b45.
Antimicrobial resistance (AMR) poses an emergent threat to global health due to antibiotic abuse, overuse and misuse, necessitating urgent innovative and sustainable solutions. The utilization of bio-nanomaterials as antibiotic allies is a green, economic, sustainable and renewable strategy to combat this pressing issue. These biomaterials involve green precursors (e.g. biowaste, plant extracts, essential oil, microbes, and agricultural residue) and techniques for their fabrication, which reduce their cyto/environmental toxicity and exhibit economic manufacturing, enabling a waste-to-wealth circular economy module. Their nanoscale dimensions with augmented biocompatibility characterize bio-nanomaterials and offer distinctive advantages in addressing AMR. Their ability to target pathogens, such as bacteria and viruses, at the molecular level, coupled with their diverse functionalities and bio-functionality doping from natural precursors, allows for a multifaceted approach to combat resistance. Furthermore, bio-nanomaterials can be tailored to enhance the efficacy of existing antimicrobial agents or deliver novel therapies, presenting a versatile platform for innovation. Their use in combination with traditional antibiotics can mitigate resistance mechanisms, prolong the effectiveness of existing treatments, and reduce side effects. This review aims to shed light on the potential of bio-nanomaterials in countering AMR, related mechanisms, and their applications in various domains. These roles encompass co-therapy, nanoencapsulation, and antimicrobial stewardship, each offering a distinct avenue for overcoming AMR. Besides, it addresses the challenges associated with bio-nanomaterials, emphasizing the importance of regulatory considerations. These green biomaterials are the near future of One Health Care, which will have economic, non-polluting, non-toxic, anti-resistant, biocompatible, degradable, and repurposable avenues, contributing to sustainable development goals.
抗生素耐药性(AMR)由于抗生素滥用、过度使用和误用,对全球健康构成了紧急威胁,需要紧急创新和可持续的解决方案。生物纳米材料作为抗生素盟友的应用是一种绿色、经济、可持续和可再生的策略,可用于应对这一紧迫问题。这些生物材料涉及绿色前体(如生物废物、植物提取物、精油、微生物和农业残留物)及其制造技术,这些技术可降低其细胞/环境毒性,并具有经济的制造能力,从而实现废物到财富的循环经济模块。它们的纳米尺寸和增强的生物相容性使生物纳米材料具有特色,并在解决 AMR 方面具有独特的优势。它们能够在分子水平上靶向病原体,如细菌和病毒,并且具有多样化的功能和生物功能掺杂自天然前体,可提供一种多方面的方法来对抗耐药性。此外,生物纳米材料可以进行定制,以增强现有抗菌剂的功效或提供新的治疗方法,为创新提供了一个多功能平台。它们与传统抗生素联合使用可以减轻耐药机制,延长现有治疗的效果,并减少副作用。本综述旨在探讨生物纳米材料在对抗 AMR 中的潜力、相关机制以及它们在各个领域的应用。这些作用包括联合治疗、纳米封装和抗菌药物管理,每个作用都为克服 AMR 提供了独特的途径。此外,它还解决了与生物纳米材料相关的挑战,强调了监管考虑的重要性。这些绿色生物材料是未来的“One Health Care”,它们将具有经济、无污染、无毒、抗耐药性、生物相容性、可降解和可重复使用的特点,为可持续发展目标做出贡献。